Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation

Ying Lu, Zhao Hui Wang, Tonglei Li, Helen McNally, Kinam Park, Michael Sturek

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The aim of the present study was to prepare and evaluate a paclitaxel nanocrystal-based formulation stabilized by serum protein transferrin in a non-covalent manner. The pure paclitaxel nanocrystals were first prepared using an antisolvent precipitation method augmented by sonication. The serum protein transferrin was selected for use after evaluating the stabilizing effect of several serum proteins including albumin and immunoglobulin G. The formulation contained approximately 55-60% drug and was stable for at least 3 months at 4 C. In vivo antitumor efficacy studies using mice inoculated with KB cells demonstrate significantly higher tumor inhibition rate of 45.1% for paclitaxel-transferrin formulation compared to 28.8% for paclitaxel nanosuspension treatment alone. Interestingly, the Taxol® formulation showed higher antitumor activity than the paclitaxel-transferrin formulation, achieving a 93.3% tumor inhibition rate 12 days post initial dosing. However, the paclitaxel-transferrin formulation showed a lower level of toxicity, which is indicated by a steady increase in body weight of mice over the treatment period. In comparison, treatment with Taxol® resulted in toxicity issues as body weight decreased. These results suggest the potential benefit of using a serum protein in a non-covalent manner in conjunction with paclitaxel nanocrystals as a promising drug delivery model for anticancer therapy.

Original languageEnglish
Pages (from-to)76-85
Number of pages10
JournalJournal of Controlled Release
Volume176
Issue number1
DOIs
StatePublished - Feb 28 2014

Fingerprint

Paclitaxel
Nanoparticles
Blood Proteins
Transferrin
Body Weight
KB Cells
Sonication
Pharmaceutical Preparations
paclitaxel-transferrin
Albumins
Neoplasms
Immunoglobulin G

Keywords

  • Albumin
  • Antitumor fficacy
  • Keywords
  • Nanocrystal
  • Paclitaxel
  • Taxol
  • Transferrin

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation. / Lu, Ying; Wang, Zhao Hui; Li, Tonglei; McNally, Helen; Park, Kinam; Sturek, Michael.

In: Journal of Controlled Release, Vol. 176, No. 1, 28.02.2014, p. 76-85.

Research output: Contribution to journalArticle

Lu, Ying ; Wang, Zhao Hui ; Li, Tonglei ; McNally, Helen ; Park, Kinam ; Sturek, Michael. / Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation. In: Journal of Controlled Release. 2014 ; Vol. 176, No. 1. pp. 76-85.
@article{4d625b10e4d54edeb5adbc0eb699ca81,
title = "Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation",
abstract = "The aim of the present study was to prepare and evaluate a paclitaxel nanocrystal-based formulation stabilized by serum protein transferrin in a non-covalent manner. The pure paclitaxel nanocrystals were first prepared using an antisolvent precipitation method augmented by sonication. The serum protein transferrin was selected for use after evaluating the stabilizing effect of several serum proteins including albumin and immunoglobulin G. The formulation contained approximately 55-60{\%} drug and was stable for at least 3 months at 4 C. In vivo antitumor efficacy studies using mice inoculated with KB cells demonstrate significantly higher tumor inhibition rate of 45.1{\%} for paclitaxel-transferrin formulation compared to 28.8{\%} for paclitaxel nanosuspension treatment alone. Interestingly, the Taxol{\circledR} formulation showed higher antitumor activity than the paclitaxel-transferrin formulation, achieving a 93.3{\%} tumor inhibition rate 12 days post initial dosing. However, the paclitaxel-transferrin formulation showed a lower level of toxicity, which is indicated by a steady increase in body weight of mice over the treatment period. In comparison, treatment with Taxol{\circledR} resulted in toxicity issues as body weight decreased. These results suggest the potential benefit of using a serum protein in a non-covalent manner in conjunction with paclitaxel nanocrystals as a promising drug delivery model for anticancer therapy.",
keywords = "Albumin, Antitumor fficacy, Keywords, Nanocrystal, Paclitaxel, Taxol, Transferrin",
author = "Ying Lu and Wang, {Zhao Hui} and Tonglei Li and Helen McNally and Kinam Park and Michael Sturek",
year = "2014",
month = "2",
day = "28",
doi = "10.1016/j.jconrel.2013.12.018",
language = "English",
volume = "176",
pages = "76--85",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation

AU - Lu, Ying

AU - Wang, Zhao Hui

AU - Li, Tonglei

AU - McNally, Helen

AU - Park, Kinam

AU - Sturek, Michael

PY - 2014/2/28

Y1 - 2014/2/28

N2 - The aim of the present study was to prepare and evaluate a paclitaxel nanocrystal-based formulation stabilized by serum protein transferrin in a non-covalent manner. The pure paclitaxel nanocrystals were first prepared using an antisolvent precipitation method augmented by sonication. The serum protein transferrin was selected for use after evaluating the stabilizing effect of several serum proteins including albumin and immunoglobulin G. The formulation contained approximately 55-60% drug and was stable for at least 3 months at 4 C. In vivo antitumor efficacy studies using mice inoculated with KB cells demonstrate significantly higher tumor inhibition rate of 45.1% for paclitaxel-transferrin formulation compared to 28.8% for paclitaxel nanosuspension treatment alone. Interestingly, the Taxol® formulation showed higher antitumor activity than the paclitaxel-transferrin formulation, achieving a 93.3% tumor inhibition rate 12 days post initial dosing. However, the paclitaxel-transferrin formulation showed a lower level of toxicity, which is indicated by a steady increase in body weight of mice over the treatment period. In comparison, treatment with Taxol® resulted in toxicity issues as body weight decreased. These results suggest the potential benefit of using a serum protein in a non-covalent manner in conjunction with paclitaxel nanocrystals as a promising drug delivery model for anticancer therapy.

AB - The aim of the present study was to prepare and evaluate a paclitaxel nanocrystal-based formulation stabilized by serum protein transferrin in a non-covalent manner. The pure paclitaxel nanocrystals were first prepared using an antisolvent precipitation method augmented by sonication. The serum protein transferrin was selected for use after evaluating the stabilizing effect of several serum proteins including albumin and immunoglobulin G. The formulation contained approximately 55-60% drug and was stable for at least 3 months at 4 C. In vivo antitumor efficacy studies using mice inoculated with KB cells demonstrate significantly higher tumor inhibition rate of 45.1% for paclitaxel-transferrin formulation compared to 28.8% for paclitaxel nanosuspension treatment alone. Interestingly, the Taxol® formulation showed higher antitumor activity than the paclitaxel-transferrin formulation, achieving a 93.3% tumor inhibition rate 12 days post initial dosing. However, the paclitaxel-transferrin formulation showed a lower level of toxicity, which is indicated by a steady increase in body weight of mice over the treatment period. In comparison, treatment with Taxol® resulted in toxicity issues as body weight decreased. These results suggest the potential benefit of using a serum protein in a non-covalent manner in conjunction with paclitaxel nanocrystals as a promising drug delivery model for anticancer therapy.

KW - Albumin

KW - Antitumor fficacy

KW - Keywords

KW - Nanocrystal

KW - Paclitaxel

KW - Taxol

KW - Transferrin

UR - http://www.scopus.com/inward/record.url?scp=84892595073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892595073&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2013.12.018

DO - 10.1016/j.jconrel.2013.12.018

M3 - Article

VL - 176

SP - 76

EP - 85

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -